Infectious Disease
COVID-19 Vaccine
0
Pipeline Programs↗
1
Active Trials↗
1
Companies Involved↗
COVID-19 Vaccine is an early-stage landscape with 0 programs across 1 company. The most active players are Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd..
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
6
clinical trials
Completed3 · 50%
Unknown status2 · 33%
Active, not recruiting1 · 17%
Clinical Trials
Trial Activity
6 trials
Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults
Active, not recruiting·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT07183709·30 enrolled
Safety Study of COVID19 Vaccine on the Market
Unknown status·
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.·Phase 4·NCT05890521·100,000 enrolled
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.·Phase 4·NCT05890521·100,000 enrolledParasitism & COVID19 Vaccines: New Challenge.
Unknown status·—·N/A·NCT05185778·128 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)